Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer

Inclusion Criteria

• •Age ≥ 70 years
• •Histologically or cytologically confirmed diagnosis of advanced ovarian cancer (FIGO stage III or IV)
• •PARP inhibitors -naive patient who need to initiate maintenance treatment with PARP inhibitors for the first time (according the the marketing authorization)
• •Patient with a life expectancy of more then 3 months
• •Informed patient which does not oppose to participate to the study
• •* Basal cell carcinoma or non-invasive cutaneous squamous cell carcinoma
• •* Stage 1B or less cervical carcinoma
• •* Non-invasive superficial bladder cancer